Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F

Human Pathology

Volumn 39, Issue 7, 2008, Pages 1111-1114

  Gibson, Sarah E ^a   Schade, Andrew E ^a   Szpurka, Hadrian ^b   Bak, Beata ^b   Maciejewski, Jaroslaw P ^b   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Chronic myeloproliferative disorders; MPL W515L; Phospho STAT5

Indexed keywords

BCR ABL PROTEIN; JANUS KINASE 2; STAT5 PROTEIN;

AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAK2 GENE; LABORATORY TEST; MALE; MEGAKARYOCYTE; MPL GENE; MYELOPROLIFERATIVE DISORDER; PROTEIN EXPRESSION; THROMBOCYTHEMIA;

AGED; BONE MARROW CELLS; FUSION PROTEINS, BCR-ABL; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; MALE; MEGAKARYOCYTES; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; POINT MUTATION; POLYMERASE CHAIN REACTION; RECEPTORS, THROMBOPOIETIN; STAT5 TRANSCRIPTION FACTOR;

EID: 45049087999     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.10.034     Document Type: Article

References (11)

1. Aboudola S., Murugesan G., Szpurka H., et al. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 31 (2007) 233-239
2. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
3. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
4. Flores-Morales A., Pircher T.J., Silvennoinen O., et al. In vitro interaction between STAT 5 and JAK 2; dependence upon phosphorylation status of STAT 5 and JAK 2. Mol Cell Endocrinol 138 (1998) 1-10
5. Silva M., Benito A., Sanz C., et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 274 (1999) 22165-22169
6. Lu X., Levine R., Tong W., et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 102 (2005) 18962-18967
7. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006) 3472-3476
8. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) e270
9. Murugesan G., Aboudola S., Szpurka H., et al. Identification of JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 125 (2006) 625-633
10. Ye S., Dhillon S., Ke X., et al. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 29 (2001) E88
11. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 (2007) 459-468